Pharmacokinetics and Safety of Estradiol Valerate Tablet and Its Generic: A Phase 1 Bioequivalence Study in Healthy Chinese Postmenopausal Female Subjects

References

• Dieni CV, Contemori S, Biscarini A, Panichi R. De novo synthesized estradiol: a role in modulating the cerebellar function. Int J Mol Sci. 2020;21(9):3316. doi:10.3390/ijms21093316
   PubMed Web of Science ®Google Scholar
• Duralde ER, Sobel TH, Manson JE. Management of perimenopausal and menopausal symptoms. BMJ. 2023;382:e072612. doi:10.1136/bmj-2022-072612
   PubMedGoogle Scholar
• McNeil M. Menopausal hormone therapy: understanding long-term risks and benefits. JAMA. 2017;318(10):911–913. doi:10.1001/jama.2017.11462
   PubMed Web of Science ®Google Scholar
• The Hormone Therapy Position Statement of The North American Menopause Society” Advisory P. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767–794. doi:10.1097/GME.0000000000002028
   PubMed Web of Science ®Google Scholar
• Kiley JW, Shulman LP. Estradiol valerate and dienogest: a new approach to oral contraception. Int J Womens Health. 2011;3:281–286. doi:10.2147/IJWH.S22645
   PubMedGoogle Scholar
• Micks EA, Jensen JT. Treatment of heavy menstrual bleeding with the estradiol valerate and dienogest oral contraceptive pill. Adv Ther. 2013;30(1):1–13. doi:10.1007/s12325-012-0071-3
   PubMed Web of Science ®Google Scholar
• Badawi AF, Cavalieri EL, Rogan EG. Role of human cytochrome P450 1A1, 1A2, 1B1, and 3A4 in the 2-, 4-, and 16[alpha]-hydroxylation of 17[beta]-estradiol. Metabolism. 2001;50(9):1001–1003. doi:10.1053/meta.2001.25592
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. FDA labelling information-NATAZIA (estradiol valerate and estradiol valerate/dienogest) tablets, for oral use.04/29/2022; 2022. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/022252s007lbl.pdf. Accessed July 5, 2024.
   Google Scholar
• Zimmerman H, Thebault JJ, Duvauchelle T, Mignot A, Renoux A, Gualano V. Pharmacokinetics of estradiol valerate 2mg + dienogest 2mg (climodien(R) 2/2) after single and repeated oral administration in healthy postmenopausal women. Clin Drug Investig. 2000;20(2):123–134. doi:10.2165/00044011-200020020-00007
   PubMed Web of Science ®Google Scholar
• Hoy SM, Scott LJ. Estradiol valerate/dienogest: in oral contraception. Drugs. 2009;69(12):1635–1646. doi:10.2165/11202820-000000000-00000
   PubMed Web of Science ®Google Scholar
• Zeun S, Lu M, Uddin A, Zeiler B, Morrison D, Blode H. Pharmacokinetics of an oral contraceptive containing oestradiol valerate and dienogest. Eur J Contracept Reprod Health Care. 2009;14(3):221–232. doi:10.1080/13625180902850039
   PubMed Web of Science ®Google Scholar
• Zimmermann H, Koytchev R, Mayer O, Borner A, Mellinger U, Breitbarth H. Pharmacokinetics of orally administered estradiol valerate. Results of a single-dose cross-over bioequivalence study in postmenopausal women. Arzneimittelforschung. 1998;48(9):941–947.
   PubMed Web of Science ®Google Scholar
• Timmer CJ, Geurts TB. Bioequivalence assessment of three different estradiol formulations in postmenopausal women in an open, randomized, single-dose, 3-way cross-over study. Eur J Drug Metab Pharmacokinet. 1999;24(1):47–53. doi:10.1007/BF03190010
   PubMed Web of Science ®Google Scholar
• Whalen KL, Rose R. Estradiol valerate/dienogest: a novel oral contraceptive. Ann Pharmacother. 2011;45(10):1256–1261.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Draft Guidance on Estradiol; 2010. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/psg/Estradiol_tabs_84500_84499_81295_RC_12-10.pdf. Accessed July 5, 2024.
   Google Scholar
• Kaminski J, Junior CM, Pavesi H, Drobrzenski B, Amaral GMD. Effects of oral versus transdermal estradiol plus micronized progesterone on thyroid hormones, hepatic proteins, lipids, and quality of life in menopausal women with hypothyroidism: a clinical trial. Menopause. 2021;28(9):1044–1052. doi:10.1097/GME.0000000000001811
   PubMed Web of Science ®Google Scholar
• Liu J, Xu T, Ma L, Chang W. Signal pathway of estrogen and estrogen receptor in the development of thyroid cancer. Front Oncol. 2021;11:593479.
   PubMed Web of Science ®Google Scholar
• Gong Z, Yang S, Wei M, et al. The isoforms of estrogen receptor alpha and beta in thyroid cancer. Front Oncol. 2022;12:916804. doi:10.3389/fonc.2022.916804
   PubMed Web of Science ®Google Scholar
• Liu L, Zhao T, Shan L, Cao L, Zhu X, Xue Y. Estradiol regulates intestinal ABCG2 to promote urate excretion via the PI3K/Akt pathway. Nutr Metab. 2021;18(1):63.
   Google Scholar
• Akin F, Bastemir M, Alkis E, Kaptanoglu B. SHBG levels correlate with insulin resistance in postmenopausal women. Eur J Intern Med. 2009;20(2):162–167.
   PubMed Web of Science ®Google Scholar
• Bush TL, Barrett-Connor E, Cowan LD, et al. Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the lipid research clinics program follow-up study. Circulation. 1987;75(6):1102–1109. doi:10.1161/01.CIR.75.6.1102
   PubMed Web of Science ®Google Scholar
• Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med. 1991;20(1):47–63.
   PubMed Web of Science ®Google Scholar
• Stampfer MJ, Colditz GA, Willett WC, et al. Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses’ health study. N Engl J Med. 1991;325(11):756–762. doi:10.1056/NEJM199109123251102
   PubMed Web of Science ®Google Scholar
• Whitcroft SI, Crook D, Marsh MS, Ellerington MC, Whitehead MI, Stevenson JC. Long-term effects of oral and transdermal hormone replacement therapies on serum lipid and lipoprotein concentrations. Obstet Gynecol. 1994;84(2):222–226.
   PubMed Web of Science ®Google Scholar
• Bhathena RK, Anklesaria BS, Ganatra AM, Pinto R. The influence of transdermal oestradiol replacement therapy and medroxyprogesterone acetate on serum lipids and lipoproteins. Br J Clin Pharmacol. 1998;45(2):170–172. doi:10.1046/j.1365-2125.1998.00658.x
   PubMed Web of Science ®Google Scholar
• Walsh BW, Schiff I, Rosner B, Greenberg L, Ravnikar V, Sacks FM. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med. 1991;325(17):1196–1204. doi:10.1056/NEJM199110243251702
   PubMed Web of Science ®Google Scholar
• Luo F, Guo Y, Ruan GY, Peng R, Li XP. Estrogen lowers triglyceride via regulating hepatic APOA5 expression. Lipids Health Dis. 2017;16(1):72. doi:10.1186/s12944-017-0463-0
   PubMed Web of Science ®Google Scholar